Screener
AbbVie ABBV Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from AbbVie’s reported figures.
Based on trailing twelve months.
The source filing: AbbVie’s 10-Q, filed May 8, 2026. Open the filing →
- Filed
- May 8, 2026, 12:28 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001551152-26-000017
FAQ
- What is AbbVie's return on equity?
- AbbVie (ABBV) reported return on equity of 89% in Q1 2025.
- How has AbbVie's return on equity changed year-over-year?
- AbbVie's return on equity increased by 58.0% year-over-year, from 56.3% to 89%.
- What is the long-term trend for AbbVie's return on equity?
- Over 3 years (2021 to 2024), AbbVie's return on equity has grown at a -8.3% compound annual growth rate (CAGR), from 81% to 62.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about AbbVie's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude